In today’s recent session, 0.69 million shares of the VYNE Therapeutics Inc (NASDAQ:VYNE) have been traded, and its beta is 1.32. Most recently the company’s share price was $1.67, and it changed around -$0.07 or -3.82% from the last close, which brings the market valuation of the company to $25.46M. VYNE at last check was trading at a discount to its 52-week high of $4.30, offering almost -157.49% off that amount. The share price’s 52-week low was $1.57, which indicates that the recent value has risen by an impressive 5.99% since then. We note from VYNE Therapeutics Inc’s average daily trading volume that its 10-day average is 0.2 million shares, with the 3-month average coming to 119.12K.
VYNE Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended VYNE as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. VYNE Therapeutics Inc is expected to report earnings per share of 0 for the current quarter.
VYNE Therapeutics Inc (NASDAQ:VYNE) trade information
Instantly VYNE has been showing red trend so far today with a performance of -3.82% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.9500 on recent trading dayincreased the stock’s daily price by 14.36%. The company’s shares are currently down -50.04% year-to-date, but still down -5.45% over the last five days. On the other hand, VYNE Therapeutics Inc (NASDAQ:VYNE) is -36.85% down in the 30-day period. We can see from the shorts that 0.15 million shares have been sold at a short interest cover period of 2.1 day(s).
The consensus price target as assigned by Wall Street analysts is $5.75, which translates to bulls needing to increase their stock price by 70.96% from its current value. Analyst projections state that VYNE is forecast to be at a low of $5.75 and a high of $5.75.
VYNE Therapeutics Inc (VYNE) estimates and forecasts
The year-over-year growth rate is expected to be -60.08%, down from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 50k in revenue for the current quarter. 2 analysts expect VYNE Therapeutics Inc to make 50k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 98k and 198k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -48.98%. Forecasts for the next quarter put sales growth at -74.75%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 65.87%. VYNE Therapeutics Inc earnings are expected to increase by -26.60% in 2025, but the outlook is positive 4.50% per year for the next five years.
VYNE Therapeutics Inc (NASDAQ:VYNE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.37% of VYNE Therapeutics Inc shares, and 51.02% of them are in the hands of institutional investors. The stock currently has a share float of 56.30%. VYNE Therapeutics Inc stock is held by 41.0 institutions, with STALEY CAPITAL ADVISERS INC being the largest institutional investor. By 2024-06-30, it held 0.0857% of the shares, which is about 36472.0 shares worth $71850.0.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 373.32 shares worth $0.63 million, making up 2.45% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 100.81 shares worth around $0.17 million, which represents about 0.66% of the total shares outstanding.
